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The MLL rearrangement was not constitutional. BamHI digested DNA extracted from the patient's peripheral blood lymphocytes (PBL) prior to the leukemic phase was hybridized to the 0.7B MLL probe. The MOLT 4 cell line is used as a germline control. Size standards are as indicated. A single germline fragment is seen in both the control and the patient PBL sample indicating that the MLL rearrangement seen in the tumor cells is not due to a restriction fragment length polymorphism. treatment with an alkylating agent and an epipodophyllotoxin. While it is possible that therapy-related lymphoblastic lymphoma has a longer latency period than therapy-related leukemia, wide variations in latency periods for secondary malignancies with the 11q23 translocation following similar treatment regimens have been reported. 2 What is the cause for the second malignancy in this patient? There was no history of a hereditary predisposition to malignancies in the family. To our knowledge there is no association between primary hepatocellular carcinoma and lymphoblastic lymphoma and the possibility that these were two unrelated de novo malignancies cannot be eliminated. However, the known association between 11q23 translocations and therapy-related acute leukemias make it likely that the lymphoblastic lymphoma in this patient was a direct result of an MLL translocation induced by treatment with DNA damaging agents. The mechanisms(s) of illegitimate recombination leading to MLL rearrangements is not well understood nor is the role of topo-II in this process. These topics have recently been reviewed. 3 We conclude that therapy-related lymphoblastic lymphoma can be associated with 11q23 translocations involving the MLL gene. While the case described here had a slightly longer latency period compared with the t-AMLs associated with the topo II poisons, it seems likely that the mechanism of 11q23 translocation in this patient is similar to that seen in t-AMLs associated with topo II poisons. Although this entity is presumably rare, the true frequency with which therapyrelated lymphoblastic lymphoma occurs following aggressive, multiagent chemotherapy can only be ascertained by careful follow-up of cancer survivors.
extensive BMN is characterized by the development of fever, bone pain, a leukoerythroblastic peripheral blood film, variable degrees of pancytopenia and elevations of lactate dehydrogenase and alkaline phosphatase. BMN has been reported in patients with different malignancies, sickle cell disease, disseminated intravascular coagulation (DIC), antiphospholipid syndrome (APS), as well as infections. 1 There are case reports linking certain medications including fludarabine, interferon alfa to the development of BMN as well. 2, 3 Here we report two cases of multiple myeloma (MM) with extensive BMN.
In case 1, a 45-year-old man was diagnosed with Durie-Salmon stage III MM in June 1995. A serum immunoelectrophoresis and nephelometric immunoglobulin quantitation showed 31 g/l of IgD. Urinary excretion of light chain was 3.0 g/24 h. The patient was treated with VAD (vincristine, doxorubicin and dexamethasone) and oral pulse dexamethasone therapy. He had a good response to the treatment and his serum IgD decreased to 0.052 g/l. He did well until December 1996, when he was admitted to an outside hospital with worsening fatigue and sudden onset of lower back pain without associated neurologic symptoms. Two days following the completion of the 4-day course of dexamethasone, the patient had a sudden onset of severe thoracic and lumbar back pain. His physical examination was significant for mild spinal and paraspinal tenderness throughout the thoracic and lumbar regions. His pertinent laboratory values are detailed in Table 1 . The patient was admitted to our hospital and received high-dose dexamethasone and pain control. MRI of the spine was normal. On the second hospitalization day, he reported continued, though somewhat improved pain throughout the spine, as well as similar intensity pain in the hips bilaterally. Laboratory values were significant for progressive pancytopenia, a markedly increased LDH of 17920 U/l (reference range 90-250 U/l), an elevated alkaline phosphatase of 326 U/l (reference range, 45-115 U/l), and phosphate of 6.2 mg/dl (reference range 2.6-4.5 mg/dl) ( Table 1) . A BM aspirate was attempted but the marrow was inaspirable. A BM biopsy showed atypical plasma cells and extensive necrosis; normal hematopoietic elements were virtually absent. Dexamethasone and oxymorphone were continued, filgrastim and erythropoietin injections were begun. The pain resolved subsequently. This was accompanied by a marked decrease in the serum LDH and phosphate levels at discharge (Table 1) .
Case 2 is a 45-year-old man with Durie-Salmon stage III light chain MM diagnosed in November 1994. He was treated with pulse oral dexamethasone and monthly pamidronate, as well as palliative radiation therapy to his thoracolumbar spine (T6 to L4) at a total dose of 3000 cGy. His pain resolved and his performance status improved significantly. He then received four cycles of VAD followed by three cycles of high-dose cyclophosphamide (3 g/m 2 ) for consolidation and mobilization of peripheral stem cells in preparation for autologous stem cell transplant. He remained in complete remission until June 1997, when he developed severe cervical pain and was found to have new compression fracture at T5 with marked myelomatous involvement of C2 associated with a prevertebral soft tissue mass. He was placed on a Philadelphia brace and radiation therapy was initiated with a total of 3000 cGy. Despite the initiation of dexamethasone therapy, his 24-h urine protein increased from 0.1 to 7.4 g. His laboratory values were notable for the markedly increased LDH level and hyperphosphatemia ( Table 1 ). The patient was admitted for pain control and started with dexamethasone pulse and radiation therapy to the C1-C5 spine with a total of 2200 cGy. On the sixth hospitalization day, his hemoglobin level decreased to 8.7 g/dl. A BM biopsy showed a small focus of viable and immature plasma cells with extensive necrosis; normal hematopoietic elements were virtually absent (Figures 1 and 2) . The patient had a good response to the pulse dexamethasone therapy. He then received high-dose melphalan (140 mg/m 2 ) followed by autologous stem cell transplant. After a prolonged hospitalization course, the patient was discharged in a stable condition. His laboratory values on the discharge day are shown in Table 1 .
To our knowledge, this appears to be the first description of the association of BMN with MM in the English medical literature. In the two patients described, there was no evidence for the presence of other potential triggers of BMN, such as infection, DIC or exposure to chemotherapeutic agents like fludarabine and interferon-␣ that presumably 
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Focus of viable poorly differentiated plasma cells (arrow) and necrotic plasma cells around osseous trabeculae.
Figure 2
Higher power view of the same area showing viable plasma cells (arrow) within a necrotic plasma cell infiltrate.
can cause BMN. Rather BMN in these patients occurred at the time of relapse with MM. Their clinical presentations share many of the welldescribed features typical of BMN: bone pain, increased alkaline phosphatase, and marked elevated LDH level associated with characteristic BM findings on biopsy. Although the first patient developed severe pancytopenia at the time of presentation, the second patient developed only anemia and mild thrombocytopenia. Interestingly, hyperphosphatemia was present at presentation in both patients. This apparently was not reported previously with BMN. The hyperphosphatemia was transient and might represent the high cell turnover in BMN. While extensive BMN associated with hemotologic malignancies is almost invariably a fatal complication, the prompt initiation of therapy in our patients resulted in complete restoration of hematopoiesis, relief of bone pain
